为什么会伤到视神经。FDA 自己承认找不到机制,但学界有假说——GLP-1 会轻度降压,而 NAION 恰恰最容易发生在夜间血压最低的时候。解放军总医院魏世辉团队报过一个病例:58 岁女性,剂量从 0.5 加到 1.0 毫克一个月后右眼发作,视力掉到 0.05;四个月后左眼也发作。检查发现她夜间最低舒张压只有 52 毫米汞柱,双眼都没有生理性视杯。这个“视盘拥挤”(杯盘比<0.2)才是关键:人群里两到三成的人至少一只眼是这种解剖,是 NAION 最强的单一预测因素,而他们自己不知道。
参考文献
U.S. FDA. FDA Drug Safety Communication: GLP-1 receptor agonists and risk of NAION. 2026-11-09.
新华社.《美药管局警示GLP-1类降糖药或增一种眼病风险》. 2026-11-10.
Hathaway JT, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol. 2024;142(8):732-739. DOI: 10.1001/jamaophthalmol.2024.2296
Cai CX, et al. Semaglutide and NAION Across 37 Million Patients With Type 2 Diabetes(OHDSI 多国数据库). JAMA Ophthalmol. 2025.
丹麦全国队列研究:Semaglutide 与 NAION 五年风险. PMID: 39696569
丹麦-挪威注册研究:GLP-1 RA 与 NAION 风险比. PMID: 40098249
Nogueira A, et al. Association Between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy: A Meta-analysis. 2026.
Li HY, et al. GLP-1 Receptor Agonists and Risk of Optic Nerve or Vision-Threatening Events: A Meta-analysis of Randomized Controlled Trials.
Tan S, Wei S. GLP-1 RA Associated Nonarteritic Anterior Ischemic Optic Neuropathy. WOC 2026, Prague, 2026-06-28(Hot Topics in Neuro-Ophthalmology 论坛)
Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844. DOI: 10.1056/NEJMoa1607141
European Medicines Agency, PRAC. NAION 列为司美格鲁肽“非常罕见”副作用. 2025-06.
日本 PMDA 修订说明书:司美格鲁肽(2026-05)、替尔泊肽与度拉糖肽(2026-09)
诺和诺德、礼来 2026 年前三季度财务报告
诺和诺德中国. 诺和盈® 长期体重管理适应症更新. 2026-10-21.
BrightFocus Foundation. Can GLP-1 Drugs Help Protect Vision in Glaucoma? 2026-11-09.